AFT Pharmaceuticals (ASX:AFP) signs Europe deal for Pascomer drug

Company News

by Rachael Jones

AFT Pharmaceuticals (ASX:AFP) has signed a new commercialisation and development agreement for its orphan drug Pascomer.

The agreement covers 27 countries within the European Union including Switzerland, Norway and the United Kingdom.

The agreement is with Desitin Arzneimittel GmbH, a specialist pharmaceutical company based in Germany.

Pascomer is being developed to treat facial angiofibromas, a symptom of Tuberous Sclerosis Complex, a genetic disease that can impair breathing and eyesight.

Shares in AFT Pharmaceuticals (ASX:AFP) are trading 3.7 per cent higher at $4.25

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.